European Innovation Council

Basemark specializes in developing augmented reality software for enhanced driver awareness and safety. It offers tools to avoid occlusion, prevent motion sickness, and support multiple in-vehicle displays, enabling automotive manufacturers to create practical AR applications.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Quanturi Oy is a Finnish company founded in 2016, headquartered in Espoo, with additional locations across Europe, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium. The company specializes in developing and providing continuous monitoring solutions for fermentable products, focusing on sectors such as agriculture, forestry, and waste management. Its product offerings include wireless monitoring systems for compost temperature, grain management, and hay, as well as temperature monitoring systems applicable to various other industries. Quanturi Oy also engages in online sales of its innovative solutions, emphasizing the analysis of data associated with its connected objects.

Quanturi Oy is a Finnish company founded in 2016, headquartered in Espoo, with additional locations across Europe, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium. The company specializes in developing and providing continuous monitoring solutions for fermentable products, focusing on sectors such as agriculture, forestry, and waste management. Its product offerings include wireless monitoring systems for compost temperature, grain management, and hay, as well as temperature monitoring systems applicable to various other industries. Quanturi Oy also engages in online sales of its innovative solutions, emphasizing the analysis of data associated with its connected objects.

Founded in 2016, Carbo Culture produces biochar from waste biomass using a patented process that permanently stores carbon. Its high-quality biochar is used for soil remediation and enhancement, while also generating renewable energy and creating tangible carbon credits.

Surgify is focused on the commercialization of an innovative technology designed for bone surgery, developed at Aalto University with support from the Finnish Funding Agency for Innovation. The company collaborates closely with the Neurosurgical Department of Helsinki University Central Hospital to ensure effective communication with clinicians. Surgify's technology aims to protect proximal soft structures during surgery, thereby minimizing complications such as bleeding, infections, and nerve injuries. This advancement not only enhances surgical safety but also aims to improve patient outcomes and quality of life by reducing suffering associated with these procedures.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Surgify is focused on the commercialization of an innovative technology designed for bone surgery, developed at Aalto University with support from the Finnish Funding Agency for Innovation. The company collaborates closely with the Neurosurgical Department of Helsinki University Central Hospital to ensure effective communication with clinicians. Surgify's technology aims to protect proximal soft structures during surgery, thereby minimizing complications such as bleeding, infections, and nerve injuries. This advancement not only enhances surgical safety but also aims to improve patient outcomes and quality of life by reducing suffering associated with these procedures.

Comptek Solutions is a Finnish developer specializing in advanced surface engineering for compound semiconductors. Its Kontrox quantum surface engineering process creates defect-free, crystalline surfaces on III-V materials, enabling higher-quality semiconductor devices used in CMOS manufacturing, radio frequency components, optoelectronics, power electronics, and concentrated photovoltaics. Founded in 2017 and based in Turku, the company also offers passivation technologies that mitigate aggressive oxidation, reducing atomic-level defects and improving device efficiency, reliability and manufacturability. Kontrox has demonstrated substantial performance gains in devices such as microLEDs, and the company provides customized services to fit diverse substrate and fabrication flows, helping clients produce more efficient, reliable, and affordable devices across optoelectronics, RF and power electronics markets.

Comptek Solutions is a Finnish developer specializing in advanced surface engineering for compound semiconductors. Its Kontrox quantum surface engineering process creates defect-free, crystalline surfaces on III-V materials, enabling higher-quality semiconductor devices used in CMOS manufacturing, radio frequency components, optoelectronics, power electronics, and concentrated photovoltaics. Founded in 2017 and based in Turku, the company also offers passivation technologies that mitigate aggressive oxidation, reducing atomic-level defects and improving device efficiency, reliability and manufacturability. Kontrox has demonstrated substantial performance gains in devices such as microLEDs, and the company provides customized services to fit diverse substrate and fabrication flows, helping clients produce more efficient, reliable, and affordable devices across optoelectronics, RF and power electronics markets.

Founded in 2016, Carbo Culture produces biochar from waste biomass using a patented process that permanently stores carbon. Its high-quality biochar is used for soil remediation and enhancement, while also generating renewable energy and creating tangible carbon credits.

IQM Quantum Computers, founded in 2018 and headquartered in Espoo, Finland, specializes in developing and manufacturing hardware systems for quantum computing. The company focuses on scalable hardware solutions utilizing superconducting technology to build quantum processors for universal quantum computers. By concentrating on practical applications, IQM aims to enhance quantum computing capabilities and address challenges faced by various industries and society. As a spin-out from Aalto University and the VTT Technical Research Centre of Finland, IQM has achieved significant advancements in areas such as thermal management, which are crucial for improving computational speed and information accuracy. The company's innovations position it as a leader in the global pursuit of large-scale quantum computing solutions. IQM also offers access to its hardware for research laboratories and supercomputing centers, helping businesses reduce error rates that currently limit computing performance.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

IQM Quantum Computers, founded in 2018 and headquartered in Espoo, Finland, specializes in developing and manufacturing hardware systems for quantum computing. The company focuses on scalable hardware solutions utilizing superconducting technology to build quantum processors for universal quantum computers. By concentrating on practical applications, IQM aims to enhance quantum computing capabilities and address challenges faced by various industries and society. As a spin-out from Aalto University and the VTT Technical Research Centre of Finland, IQM has achieved significant advancements in areas such as thermal management, which are crucial for improving computational speed and information accuracy. The company's innovations position it as a leader in the global pursuit of large-scale quantum computing solutions. IQM also offers access to its hardware for research laboratories and supercomputing centers, helping businesses reduce error rates that currently limit computing performance.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel treatments for medical conditions with significant unmet needs. The company has a diverse pipeline that addresses acute trauma, cancer, and inflammatory diseases. Its lead product, Traumakine, is an investigational intravenous formulation of interferon beta-1a, currently undergoing Phase III clinical trials for treating acute respiratory distress syndrome (ARDS). Another key candidate, Clevegen, is an immunotherapy designed to prevent tumor growth and metastasis by targeting immune suppressor molecules in tumors, and is in Phase I/II development. Additionally, Faron is developing D-ARDS, a diagnostic tool aimed at assessing ARDS severity and monitoring outcomes. The company collaborates with the MediCity unit of Turku University Medical School to enhance its research and development efforts. Founded in 2003, Faron Pharmaceuticals is committed to advancing innovative solutions in healthcare.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Founded in 2013 as a spin-off from the University of Helsinki's Finnish Institute for Molecular Medicine, Aiforia specializes in cloud-based microscopy and pathology. Its platform combines deep learning AI and high-performance cloud computing to provide efficient, scalable solutions for image-based diagnostics across various fields.

Founded in 1995, SSH Communications Security specializes in enterprise cybersecurity solutions. It offers products like PrivX for lean access management, Universal SSH Key Manager for key management, Tectia SSH for secure file transfer, and NQX Firewall for high-security applications. The company serves over 3000 customers globally, focusing on financial institutions and other organizations needing secure data access.

Founded in 2013, RePack manufactures and sells reusable packaging bags for individuals and clothing brands worldwide. Its products include polypropylene, polyethylene, and cardboard bags that can be returned for recycling after use, with customers rewarded with vouchers for future purchases. Operating primarily online, RePack aims to reduce waste and environmental impact associated with single-use packaging.

Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.

Imaqen Ltd. is a Finnish healthcare technology company developing a new pre-screening solution for early detection of cancer. The innovation offers a non-invasive patient examination and it is suitable for use in wide range of healthcare facilities. The utilised method is protected by patents. Their team consists of experienced diagnostic imaging and clinical research professionals with solid track records in successful product development and global sales and marketing.

Valtavalo Ltd, established in 2008, specializes in the development, manufacture, and supply of energy-efficient lighting solutions in Finland and internationally. Recognized as the largest LED tube manufacturer in the Northern Countries, the company focuses on high-volume production to offer competitive pricing on advanced LED technologies, which have traditionally been perceived as costly. Valtavalo's product range includes long-lifetime LED lighting tubes equipped with replaceable light sources, allowing users to significantly lower their energy consumption, installation, and maintenance costs. Through its innovative approach, Valtavalo aims to make energy-efficient lighting accessible and affordable for a wide array of clients.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.